Clinical trial
A Study to Diagnose Lung Cancer by Sputum Cytology (01-312)
NCT00210080 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00210080 |
|---|---|
| Title | A Study to Diagnose Lung Cancer by Sputum Cytology (01-312) |
| Official title | A Double-Blind, Placebo-Controlled, Parallel Group Study of Uridine 5'-Triphosphate (UTP) Solution for Inhalation as an Adjunct in the Diagnosis of Lung Cancer by Sputum Cytology |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Uridine 5'-Triphosphate (UTP) Solution for Inhalation |
| Enrollment | 700 |
| Start date | Apr 1, 2001 |
| Primary completion | Dec 1, 2003 |
| Completion | Dec 1, 2003 |
| First posted | Sep 21, 2005 |
| Last update posted | Sep 4, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: